Dr. Shai Gozani
Thank you, Tom.
review in to principles: about and in leading the the take two So our first forward as being to drive and quarter outlined, this are second It's opportunity near industry profitability are to core business attain strategy. we Tom our the I innovation company's pleased for the go around product long-term to with will built is growth. with optimistic XXXX. our prospects term; performance the continue fourth
and-a-half, an cost have throughout structure year for Focusing we business. past the as we have attainment this we To profitability; the profitability. prioritized first efficient established on of communicated end, have
full is headcount Our part-time several XX contractors. and employees time
We margins. gross marketing led expenses has and manufacturing, and and improved have distribution to optimized operating which lower
the realize commitment to The and of of ability XXXX reflects quarter provided these of our evidence front. this fourth Our on employees. our progress talent efficiencies
and an magnitude the to COVID-XX operating to maintain $XXX,XXX, We that provide position in turn time we follows corner get cash? operating of business reported, question similar third in year. In start to for target cores our specific these to shareholders not and income loss is expectation investments of in make We consistently in customers. some we we to to this the a answer uncertainty a to growth. on improvement net to due more quarter. when at will because opportunistic As around need loss will which our show flexibility year-over-year impact a are our with generate need is for the our of this initiatives the outcomes continued we Nevertheless, experience profitability
initiatives. Moving and market our to innovation expansion
Our quality innovative and life. corporate medical physicians health of patients them improve mission to is develop and bring to devices and to
products unquestionably is neuropathy advanced sophisticated in categories, most Our non-invasive the and diagnostics neuro-stimulation. their are or whether that
have investment a focus and will historical We continue maintain in R&D. and to
quarter. We an sensor all which includes and previously elements have platform, primary fourth software. Advantage launched Medicare features biosensor a of our requested enterprise in quarter release device bio DPNCheck updated this the insurance management to target and by neuro-diagnostic reporting which It we the the in reporting the the includes security new are itself, updating customer and expect announced, associated plans, data data the management U.S. As software we're
and platform: targeting. indications relief the chronic lower additional for Moving leading pain, specifically four Quell leg wearable restless musculoskeletal RLS. we believe uses pain or induced we or these clinical are ones Quell, CIPN to There for Quell, that but fibromyalgia, syndrome chemotherapy there the neuropathy are extremity are are peripheral
knee clinical extremity well-suited available which is application its and of chronic world. affects XXX,XXX lower chronic current Health Quell chronic the data with to wearable the that chronic musculoskeletal during focus now Quell pain includes it up of one pain, from repositories for Cloud U.S. primarily The users making near largest adults designs and over-the-counter pain the is nearly particularly in placement market is activity. Quell enables in pain, because Our XX% use novel the knee this of
data real-world this to the improve research. and clinical mining conduct are We product
not to that primary come business engine over-the-counter for the its growth for Quell opportunity Quell is specific will clinical believe device. profitable application as prescription indications the Beyond us, from we the medical which a
in areas I before: RLS. the well-suited In to million on with as up induced that CIPN fibromyalgia, and represent mentioned XX is three of We neuropathy to syndrome individuals are Quell leg alone significant treatment needs U.S. chemotherapy a conditions market peripheral combination, address. working again restless unmet these
This of Boston. sham-controlled submission in We in next of at business milestone leverage have or to data for trial treat clinical is fibromyalgia. symptoms conducted and The blind randomized data all randomized encouraging for our a Quell Hospital prescription trial Women's the Brigham double filing controlled a XXX(k) pilot a obtained will three.
in plan this is current third of Our file year. to quarter the
As outcome. novel complex stimulation claim this is to nerve the challenging electrical is a for and handicap and a fibromyalgia we transcutaneous treat, cannot regulatory condition
based FDA. we data present on optimistic are we the to However, the intend to
communicate of School peripheral the have additional chemotherapy strategy following We certainty. market Rochester Quell regulatory Medicine. an our will once in by sham-controlled We're we University neuropathy randomized run has induced been trial that multicenter NIH-funded of also closely of
of this regulatory We We strategy next on updates are CIPN second and the our the currently half planning steps. year. have constructing should in program
is to report not however, along users class, over Our who asset as the program indications, restless in two health have chronic XX,XXX Quell RLS pain. has -- as in far unique we addition leg syndrome other a data and from relevant RLS -- Quell having the which
this set and analyzing valuable insights. are large RLS for real world clinical marketing We and growing data
NeuroMetrix targeting has are markets large needs. with So summary, in products unmet novel
attain to organization point. prepared growth. committed be comments. questions supporting structured We'll concludes that take our operationally profitability are an are and happy to We while And at that efficient this
